Keywords : Irritable bowel syndrome , kidney disease
This report is a source for data, analysis and actionable intelligence on the IR Diagnostyx Inc. portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover data on product description, functi...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report is a source for data, analysis and actionable intelligence on the IR Diagnostyx Inc. portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.
Each pipeline product is profiled to cover data on product description, function, technology, indication, and application. The report is also supplemented with a detailed industry player profile and data on clinical trials, wherever applicable.
Scope of the Research
- Detailed industry player profile with data on business description, key industry player facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the new product development, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional data on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with data on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.
Reasons to Buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ new product development through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.
Pathology Industry
Data table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 3
Key Facts 4
IR Diagnostyx Inc. - Major Products and Services 5
IR Diagnostyx Inc. Pipeline Products by Equipment Type 6
IR Diagnostyx Inc. Pipeline Products by Development Stage 7
IR Diagnostyx Inc. Pipeline Products by Therapy Area 8
Chronic Fatigue Syndrome (CFS) Diagnostic Test 9
Product Status 9
Product Description 9
Chronic Kidney Disease Diagnostic Test 9
Product Status 9
Product Description 9
Fibromyalgia Diagnostic Test 10
Product Status 10
Product Description 10
Interstitial Cystitis Diagnostic Test 10
Product Status 10
Product Description 10
Irritable Bowel Syndrome Diagnostic Test 11
Product Status 11
Product Description 11
IR Diagnostyx Inc. - Top Competitors 12
IR Diagnostyx Inc. - Key Executives 13
IR Diagnostyx Inc. - Operations and Subsidiaries 14
Head Office 14
Appendix 15
Methodology 15
About GlobalData 15
Contact Us 15
Disclaimer 15
List of Tables
IR Diagnostyx Inc., Major development 1
IR Diagnostyx Inc. Key Pipeline Products by Equipment Type 1
IR Diagnostyx Inc. Key Pipeline Products by Therapy Area 1
IR Diagnostyx Inc. Key Pipeline Products by Development Stage 1
IR Diagnostyx Inc. Key Pipeline Products by Trial Phase 1
IR Diagnostyx Inc., Major development 4
IR Diagnostyx Inc., Major Products and Services 5
IR Diagnostyx Inc. Number of Pipeline Products by Equipment Type 6
IR Diagnostyx Inc. Pipeline Products by Equipment Type 6
IR Diagnostyx Inc. Number of Pipeline Products by Development Stage 7
IR Diagnostyx Inc. Pipeline Products by Development Stage 7
IR Diagnostyx Inc. Number of Pipeline Products by Therapy Area 8
IR Diagnostyx Inc. Pipeline Products by Therapy Area 8
Chronic Fatigue Syndrome (CFS) Diagnostic Test - Product Status 9
Chronic Fatigue Syndrome (CFS) Diagnostic Test - Product Description 9
Chronic Kidney Disease Diagnostic Test - Product Status 9
Chronic Kidney Disease Diagnostic Test - Product Description 9
Fibromyalgia Diagnostic Test - Product Status 10
Fibromyalgia Diagnostic Test - Product Description 10
Interstitial Cystitis Diagnostic Test - Product Status 10
Interstitial Cystitis Diagnostic Test - Product Description 10
Irritable Bowel Syndrome Diagnostic Test - Product Status 11
Irritable Bowel Syndrome Diagnostic Test - Product Description 11
IR Diagnostyx Inc., Key Executives 13
List of Figures
IR Diagnostyx Inc. Pipeline Products by Equipment Type 6
IR Diagnostyx Inc. Pipeline Products by Development Stage 7
IR Diagnostyx Inc. Pipeline Products by Therapy Area 8
Companies mentioned PrognosDx Health, Inc.
Molecular Cloning Laboratories
Integrated DNA Technologies, Inc.
InVitro International
AdvanDx, Inc.